Eva Peñas-LLedó1, Enrique Terán2, Marta Sosa-Macías3, Carlos Galaviz-Hernández3, Jose-Pedro Gil4, Sujit Nair5, Shyam Diwakar6, Isabel Hernández7, Julio Lara-Riegos8, Ronald Ramírez-Roa9, Ignacio Verde10, Eduardo Tarazona-Santos11, Juan Molina-Guarneros12, Graciela Moya13, Lembit Rägo14, Adrián LLerena15. 1. INUBE Extremadura Biosanitary University Research Institute, University of Extremadura, Badajoz, Spain; University of Conscientiousness Project, Campus PHI, Acebo, Extremadura, Spain. 2. Universidad San Francisco de Quito, Quito, Ecuador. 3. Instituto Politécnico Nacional, CIIDIR Unidad Durango, Durango, Mexico. 4. Karolinska Institute, Stockholm, Sweden. 5. University of Mumbai, Mumbai, India. 6. Amrita Vishwa Vidyapeetham, Kollam, Kerala, India. 7. Pontificia Universidad Católica de Ecuador, Quito, Ecuador. 8. Universidad Autónoma de Yucatán, Mérida, Yucatán, Mexico. 9. Universidad Nacional Autónoma de Nicaragua, León, Nicaragua. 10. Universidade da Beira Interior, Covilhã, Portugal. 11. Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Universidad Peruana Cayetano Heredia, Lima, Peru. 12. Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico. 13. Pontificia Universidad Católica Argentina, Buenos Aires, Argentina. 14. CIOMS Council for International Organizations of Medical Sciences, Geneva, Switzerland. 15. INUBE Extremadura Biosanitary University Research Institute, University of Extremadura, Badajoz, Spain; University of Conscientiousness Project, Campus PHI, Acebo, Extremadura, Spain. Electronic address: allerena@unex.es.
Abstract
PURPOSE: The symposium Health and Medicines in Indigenous Populations of America was organized by the Council for International Organizations of Medical Sciences (CIOMS) Working Group on Clinical Research in Resource-Limited Settings (RLSs) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF). It was aimed to share and evaluate investigators' experiences on challenges and opportunities on clinical research and pharmacogenetics. METHODS: A total of 33 members from 22 countries participated in 2 sessions: RIBEF studies on population pharmacogenetics about the relationship between ancestry with relevant drug-related genetic polymorphisms and the relationship between genotype and phenotype in Native Americans (session 1) and case examples of clinical studies in RLSs from Asia (cancer), America (diabetes and women health), and Africa (malaria) in which the participants were asked to answer in free text their experiences on challenges and opportunities to solve the problems (session 2). Later, a discourse analysis grouping common themes by affinity was conducted. FINDINGS: The main result of session 1 was that the pharmacogenetics-related ancestry of the population should be considered when designing clinical studies in RLSs. In session 2, 21 challenges and 20 opportunities were identified. The social aspects represent the largest proportion of the challenges (43%) and opportunities (55%), and some of them seem to be common. IMPLICATIONS: The main discussion points were gathered in the Declaration of Mérida/T'Hó and announced on the Parliament of Extremadura during the CIOMS-RIBEF meeting in 4 of the major Latin American autochthonous languages (Náhualth, Mayan, Miskito, and Kichwa). The declaration highlighted the following: (1) the relevance of population pharmacogenetics, (2) the sociocultural contexts (interaction with traditional medicine), and (3) the education needs of research teams for clinical research in vulnerable and autochthonous populations.
PURPOSE: The symposium Health and Medicines in Indigenous Populations of America was organized by the Council for International Organizations of Medical Sciences (CIOMS) Working Group on Clinical Research in Resource-Limited Settings (RLSs) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF). It was aimed to share and evaluate investigators' experiences on challenges and opportunities on clinical research and pharmacogenetics. METHODS: A total of 33 members from 22 countries participated in 2 sessions: RIBEF studies on population pharmacogenetics about the relationship between ancestry with relevant drug-related genetic polymorphisms and the relationship between genotype and phenotype in Native Americans (session 1) and case examples of clinical studies in RLSs from Asia (cancer), America (diabetes and women health), and Africa (malaria) in which the participants were asked to answer in free text their experiences on challenges and opportunities to solve the problems (session 2). Later, a discourse analysis grouping common themes by affinity was conducted. FINDINGS: The main result of session 1 was that the pharmacogenetics-related ancestry of the population should be considered when designing clinical studies in RLSs. In session 2, 21 challenges and 20 opportunities were identified. The social aspects represent the largest proportion of the challenges (43%) and opportunities (55%), and some of them seem to be common. IMPLICATIONS: The main discussion points were gathered in the Declaration of Mérida/T'Hó and announced on the Parliament of Extremadura during the CIOMS-RIBEF meeting in 4 of the major Latin American autochthonous languages (Náhualth, Mayan, Miskito, and Kichwa). The declaration highlighted the following: (1) the relevance of population pharmacogenetics, (2) the sociocultural contexts (interaction with traditional medicine), and (3) the education needs of research teams for clinical research in vulnerable and autochthonous populations.
Authors: Lidia Habtemikael; Mulugeta Russom; Iyassu Bahta; Selam Mihreteab; Araia Berhane; Andreas Mårtensson; Jose Pedro Gil Journal: Pharmgenomics Pers Med Date: 2020-11-12